Celcuity

76 articles about Celcuity

• Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial

  11/15/2021

  Celcuity Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance (palbociclib) for use in Celcuity's Phase 3 clinical trial at no cost to Celcuity.

• Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

  11/9/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences.

• Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/8/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, announced financial results for the third quarter ended September 30, 2021 and summarized recent business progress.

• Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

  10/29/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021.

• Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases

  10/18/2021

  Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases

• Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Celcuity today announced financial results for the second quarter ended June 30, 2021 and summarized recent business progress.

• Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

  8/5/2021

  Celcuity Inc.today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021.

• Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast

  8/2/2021

  Celcuity Inc. today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021.

• Celcuity to Participate in the William Blair Biotech Focus Conference

  7/8/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021.

• Celcuity Announces Pricing of Follow-on Offering

  6/28/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $25.00 per share.

• Celcuity Announces Launch of Follow-on Offering

  6/28/2021

  Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced that it has commenced an underwritten public offering of shares of its common stock.

• Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations

  6/9/2021

  Celcuity Inc. today announced the addition of two new senior executives. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development and Jill Krause joined as VP of Clinical Operations.

• Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast

  4/26/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the first quarter 2021 after the stock market close on Monday, May 10, 2021. Management will host a webcast/conference call the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.

• Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib

  4/12/2021

  Celcuity Inc. presented results of studies evaluating gedatolisib (a pan-PI3K/mTOR inhibitor), inavolisib (a PI3K-α inhibitor), and navitoclax (a BCL inhibitor) in breast and ovarian patient tumors.

• 

  Celcuity and Pfizer Enter Agreement for Breast Cancer Drug Following Positive Data

  4/9/2021

  Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer. 

• Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update

  4/8/2021

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today reported preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus Ibrance and endocrine therapy,

• Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer

  4/8/2021

  Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced it has entered into a global licensing agreement with Pfizer Inc. (NYSE:PFE) granting Celcuity exclusive rights to Pfizer’s gedatolisib, a Phase 1b pan-PI3K/mTOR inhibitor.

• Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

  3/16/2021

  - Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA ® and Puma’s NERLYNX ® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test - This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies

• Celcuity Announces Closing of Common Stock Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

  3/1/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the closing, on February 26, 2021, of its previously announced underwritten public offering of 1,971,100 shares of its common stock,

• Celcuity Prices Upsized Public Offering of Common Stock

  2/24/2021

  Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3 rd generation diagnostics and expanded therapeutic options for cancer patients, today announced the pricing of its previously announced underwritten public offering of 1,714,000 shares of its common stock at a price to the public of $14.00 per share. Gross proceeds to Celcuity from the offering are expected to be approxima